Nuvectis Pharma (NASDAQ:NVCT) Posts Earnings Results, Beats Expectations By $0.04 EPS

Nuvectis Pharma (NASDAQ:NVCT) announced its quarterly earnings data on Wednesday. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04, FiscalAI reports.

Here are the key takeaways from Nuvectis Pharma’s conference call:

• NXP100 has moved into commercial-stage development in China: Ciprocopan was approved for treatment-naive PNH patients after a Phase III study that management said outperformed Soliris on the primary and key secondary endpoints. A second Chinese PNH approval, for previously treated patients, is expected in Q1 2027.
• The U.S. PNH pathway remains uncertain and may require new trials. FDA discussions are ongoing; although management said the agency’s questions about the China studies were addressed, it realistically expects at least one U.S. study and is preparing for possibilities ranging from one to two trials.
• NXP100 could have opportunities beyond PNH, though evidence is still developing. Its China Phase II IgA nephropathy results included a 57% proteinuria reduction and an improvement in eGFR; a larger Phase III readout is expected around April or May 2027, and the company plans to pursue additional U.S. indications.
• NXP200 showed encouraging early activity in glioma. Management cited a 40% response rate in the 20-patient high-grade glioma cohort, including three complete responses, and plans a U.S. IND by year-end with a Phase I-B study targeted for early 2027. Further China data across other tumor types is expected in the next few months.
• Cash provides runway into the second half of 2029. Nuvectis ended the quarter with about $140 million, following a $150 million follow-on offering and roughly $37 million raised through its ATM; management says the funds should support multiple pipeline milestones.

Nuvectis Pharma Stock Down 4.8%

Shares of NVCT stock traded down $0.92 on Wednesday, reaching $18.42. 283,448 shares of the stock were exchanged, compared to its average volume of 173,701. The stock has a market cap of $601.23 million, a P/E ratio of -14.06 and a beta of -0.21. The firm has a 50 day moving average of $21.27 and a two-hundred day moving average of $14.72. Nuvectis Pharma has a 1-year low of $5.55 and a 1-year high of $29.27.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Weiss Ratings raised Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. Lucid Cap Mkts raised shares of Nuvectis Pharma to a “strong-buy” rating in a research note on Tuesday, September 1st. Loop Capital set a $40.00 price objective on shares of Nuvectis Pharma in a research note on Tuesday, September 1st. Cantor Fitzgerald began coverage on shares of Nuvectis Pharma in a report on Monday, August 24th. They set an “overweight” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $39.00 target price on shares of Nuvectis Pharma in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.25.

About Nuvectis Pharma

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.